Renal dysfunction with tenofovir disoproxil fumarate-containing highly active antiretroviral therapy regimens is not observed more frequently - A cohort and case-control study

被引:119
作者
Jones, R
Stebbing, J
Nelson, M
Moyle, G
Bower, M
Mandalia, S
Gazzard, B
机构
[1] Chelsea & Westminster Hosp, Dept HIV & Genitourinary Med, London SW10 9NH, England
[2] Univ London Imperial Coll Sci Technol & Med, Chelsea & Westminster Hosp, Div Invest Sci,Dept Immunol, Fac Med, London, England
关键词
tenofovir DF; highly active antiretroviral therapy; renal; cohort; creatinine;
D O I
10.1097/01.qai.0000138983.45235.02
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Tenofovir disoproxil fumarate (tenofovir DF), the first nucleotide analogue reverse transcriptase inhibitor approved for the treatment of HIV infection, has been associated with renal dysfunction in isolated cases. We investigated the overall incidence and risk of renal dysfunction in individuals receiving tenofovir DF and compared this with other antiretrovirals. Methods: Data from the Chelsea and Westminster cohort were analyzed to reveal HIV-positive individuals with a creatinine value greater than 120 mumol/L at any time, the upper limit of normal used by our reference laboratory. These individuals were classified according to antiretroviral exposure and time exposed. A matched case-control study was performed comparing patients who had received tenofovir DF and subsequently developed a creatinine value greater than 120 mumol/L against controls who had been treated with tenofovir DF and had not experienced a creatinine elevation. Results: Of 4183 HIV-positive patients, 1175 were identified as having a recorded creatinine value >120 mumol/L. Comparison of antiretroviral-naive patients and patients exposed to tenofovir DF- and non-tenofovir DF-containing regimens revealed a lower rate ratio and probability of developing a creatinine value >120 mumol/L in patients exposed to tenofovir DF (rate ratio vs. no antiretrovirals = 0.22, 95% confidence interval [CI]: 0.07-0.69; P < 0.001) with no significant difference between HAART regimens, corrected for duration of exposure. Of the 1058 individuals who were exposed to tenofovir DF, 84 (8%) patients experienced a creatinine value >120 mumol/L subsequent to exposure. An alternative etiology of renal dysfunction was found in 75 (90%) of these individuals. Conclusions: Tenofovir DF is not associated with renal dysfunction more frequently than other antiretroviral drugs, and the occurrence of renal dysfunction in this context is usually attributable to other causes.
引用
收藏
页码:1489 / 1495
页数:7
相关论文
共 25 条
  • [1] Tenofovir disoproxil fumarate in patients with HIV and lamivudine-resistant hepatitis B virus.
    Benhamou, Y
    Tubiana, R
    Thibault, V
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2003, 348 (02) : 177 - 178
  • [2] Safety and efficacy of adefovir dipivoxil in patients co-infected with HIV-1 and lamivudine-resistant hepatitis B virus: an open-label pilot study
    Benhamou, Y
    Bochet, M
    Thibault, V
    Calvez, V
    Fievet, MH
    Vig, P
    Gibbs, CS
    Brosgart, C
    Fry, J
    Namini, H
    Katiama, C
    Poynard, T
    [J]. LANCET, 2001, 358 (9283) : 718 - 723
  • [3] AIDS RESEARCH - NEW DRUG SHOWS PROMISE IN MONKEYS
    COHEN, J
    [J]. SCIENCE, 1995, 270 (5239) : 1121 - 1122
  • [4] HIV-1 kills renal tubular epithelial cells in vitro by triggering an apoptotic pathway involving caspase activation and fas upregulation
    Conaldi, PG
    Biancone, L
    Bottelli, A
    Wade-Evans, A
    Racusen, LC
    Boccellino, M
    Orlandi, V
    Serra, C
    Camussi, G
    Toniolo, A
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 1998, 102 (12) : 2041 - 2049
  • [5] Renal lesions in HIV-1-positive patient treated with tenofovir
    Créput, C
    Gonzalez-Canali, G
    Hill, G
    Piketty, C
    Kazatchkine, M
    Nochy, D
    [J]. AIDS, 2003, 17 (06) : 935 - 937
  • [6] New developments in anti-HIV chemotherapy
    De Clercq, E
    [J]. CURRENT MEDICINAL CHEMISTRY, 2001, 8 (13) : 1543 - 1572
  • [7] Safety, pharmacokinetics, and antiretroviral activity of intravenous 9-[2-(R)-(phosphonomethoxy)propyl]adenine a novel anti-human immunodeficiency virus (HIV) therapy, in HIV-infected adults
    Deeks, SG
    Barditch-Crovo, P
    Lietman, PS
    Hwang, F
    Cundy, KC
    Rooney, JF
    Hellmann, NS
    Safrin, S
    Kahn, JO
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1998, 42 (09) : 2380 - 2384
  • [8] Tenofovir disoproxil fumarate: A nucleotide reverse transcriptase inhibitor for the treatment of HIV infection
    Fung, HB
    Stone, EA
    Piacenti, FJ
    [J]. CLINICAL THERAPEUTICS, 2002, 24 (10) : 1515 - 1548
  • [9] Tenofovir disoproxil fumarate
    Gallant, JE
    Deresinski, S
    [J]. CLINICAL INFECTIOUS DISEASES, 2003, 37 (07) : 944 - 950
  • [10] Perspective - Increasing choices for HIV therapy
    Hammer, SM
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (26) : 2022 - 2023